Table 1 Baseline characteristics prior to first subsequent therapy

Median age

57 (37–77)

Gender

Male: 85%

Female: 15%

PS

0: 73%

1: 27%

IMDC risk group

Favourable: 27%

Intermediate: 52%

Poor: 21%

Location of metastases

Lung: 76%

Lymph nodes: 52%

Bone: 30%

Liver: 21%

Locoregional: 21%

Prior nephrectomy

64%

IC regimen

Atezolizumab/bevacizumab: 64%

Ipilimumab/nivolumab: 33%

Axitinib/avelumab: 3%

Number of subsequent systemic therapies

1: 100%

2: 36%

≥3: 15%

First subsequent systemic therapy (n = 31)

Axitinib: 48%

Cabozantinib 12%

Pazopanib: 27%

Sunitinib: 12%

Second subsequent systemic therapy (n = 12)

Axitinib: 25%

Cabozantinib: 8%

HIF inhibitor: 8%

Lenvatinib/everolimus: 8%

mTOR inhibitor: 8%

Nivolumab: 8%

Sorafenib: 8%

Sunitinib: 8%

Tivozanib: 8%

Third subsequent systemic therapy (n = 5)

Cabozantinib: 80%

Everolimus: 20%